Get the Stockscreener App
79.29
1.50%
1.17
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $79.29, with a volume of 11.90M.
It is up +1.50% in the last 24 hours and down -3.08% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$78.12
Open:
$78.02
24h Volume:
11.90M
Relative Volume:
0.80
Market Cap:
$199.10B
Revenue:
$63.62B
Net Income/Loss:
$16.41B
P/E Ratio:
12.22
EPS:
6.49
Net Cash Flow:
$17.04B
1W Performance:
-6.40%
1M Performance:
-3.08%
6M Performance:
-19.76%
1Y Performance:
-30.34%
1-Day Range:
$77.53
$79.87
1-Week Range:
$76.66
$84.97
52-Week Range:
$73.31
$120.30
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer - Insider Monkey
Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewswire Inc.
N.J.-based Merck announces $3B in cost cutting measures including layoffs - NJ.com
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - Insider Monkey
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns - Benzinga
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript - Insider Monkey
Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE - insights.citeline.com
Merck Stock Is Almost A Classical Benjamin Graham Investment - Seeking Alpha
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed - TradingView
Merck will lay off employees and shed some real estate to cut $3 billion in costs - MSN
Earnings call transcript: Merck Q2 2025 beats EPS, stock dips on revenue miss - Investing.com
Why Is Merck Stock Falling On Tuesday?Merck & Co (NYSE:MRK) - Benzinga
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales - AlphaStreet
Merck Cuts $3 Billion in Costs as Keytruda Reign Nears End - MSN
Merck posts Q2 earnings miss, unveils cost-cutting initiative - Proactive financial news
Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms - Bloomberg
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results - Tokenist
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - BioSpace
Merck & Co. Announces New Restructuring Program - TipRanks
Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2 (NYSE:MRK) - Seeking Alpha
Merck plans $3B annual cost cuts as Keytruda faces patent cliff (MRK:NYSE) - Seeking Alpha
Merck & Co Inc. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Merck Q2 Earnings Preview: What to expect? - Seeking Alpha
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings - Benzinga
Merck & Co., Inc. Earnings Preview: Insights and ExpectationsNews and Statistics - IndexBox
Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115 - Insider Monkey
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup - Insider Monkey
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase - MSN
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - MSN
Companion Animal Medicine Market Key Players AnalysisMerck & - openPR.com
Merck Announces Fourth-Quarter 2025 Dividend - BioSpace
Merck Declares $0.81 Per Share Q4 Dividend: Key Dates and Payment Details Revealed - Stock Titan
Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Nasdaq
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects? - 富途牛牛
Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times
Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - MSN
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest
Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey
Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):